
## **Christiane Gasse**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/571485/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Life-time Actionable Pharmacogenetic Drug Use: A Population-based Cohort Study in 86 040 Young People With and Without Mental Disorders in Denmark. Pharmacopsychiatry, 2022, 55, 95-107.	3.3	3
2	Effect of antipsychotics on mortality risk in patients with dementia with and without comorbidities. Journal of the American Geriatrics Society, 2022, 70, 1169-1179.	2.6	13
3	Clinical Impact of Functional CYP2C19 and CYP2D6 Gene Variants on Treatment with Antidepressants in Young People with Depression: A Danish Cohort Study. Pharmaceuticals, 2022, 15, 870.	3.8	10
4	Psychopharmacological treatment patterns prior to a schizophrenia diagnosis: A Danish nationwide study. Schizophrenia Research, 2022, 246, 268-276.	2.0	1
5	Preâ€diagnostic and postâ€diagnostic psychopharmacological treatment of 16Â288 patients with bipolar disorder. Bipolar Disorders, 2021, 23, 357-367.	1.9	15
6	Declining Use of Potentially Inappropriate Medication in People with Dementia from 2000 to 2015: A Repeated Cross-Sectional Nationwide Register-Based Study. Journal of Alzheimer's Disease, 2021, 79, 1459-1470.	2.6	6
7	Pharmacogenetic genotype and phenotype frequencies in a large Danish population-based case-cohort sample. Translational Psychiatry, 2021, 11, 294.	4.8	13
8	Risk of hospitalization and hip fracture associated with psychotropic polypharmacy in patients with dementia: A nationwide registerâ€based study. International Journal of Geriatric Psychiatry, 2021, 36, 1691-1698.	2.7	3
9	Cerebrospinal fluid test results and associations with subsequent mental disorders, neurological diseases, and CNS infections: A population-based cohort study. Brain, Behavior, and Immunity, 2021, 98, 210-218.	4.1	4
10	The Use of Opioids and Antipsychotics in Elderly with Dementia – Have Opioids Replaced Antipsychotics in Treating Behavioral Symptoms in Dementia?. Journal of Alzheimer's Disease, 2020, 73, 259-267.	2.6	18
11	Medical diseases prior to first-time depression diagnosis and subsequent risk of admissions for depression: A nationwide study of 117,585 patients. Journal of Affective Disorders, 2020, 276, 1030-1037.	4.1	3
12	The effect of combined treatment with SSRIs and renin-angiotensin system (RAS) drugs: A propensity score matched cohort study. European Neuropsychopharmacology, 2020, 32, 120-130.	0.7	4
13	Pharmacogenetics in psychiatric care, a call for uptake of available applications. Psychiatry Research, 2020, 292, 113336.	3.3	15
14	Antiepileptic Drugs and Suicide: Role of Prior Suicidal Behavior and Parental Psychiatric Disorder. Annals of Neurology, 2019, 86, 951-961.	5.3	19
15	Schizophrenia polygenic risk scores, urbanicity and treatment-resistant schizophrenia. Schizophrenia Research, 2019, 212, 79-85.	2.0	19
16	Geographical Variation in Opioid Use in Elderly Patients with Dementia: A Nationwide Study. Journal of Alzheimer's Disease, 2019, 70, 1209-1216.	2.6	11
17	Association between prior somatic disease and 5-year relapse risk among 11,856 incident patients with schizophrenia. European Psychiatry, 2019, 59, 1-7.	0.2	7
18	The association between first abortion and first-time non-fatal suicide attempt: a longitudinal cohort study of Danish population registries. Lancet Psychiatry,the, 2019, 6, 1031-1038.	7.4	11

CHRISTIANE GASSE

#	Article	IF	CITATIONS
19	Statin treatment and the risk of depression. Journal of Affective Disorders, 2019, 246, 706-715.	4.1	31
20	Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia. Schizophrenia Research, 2018, 197, 294-297.	2.0	16
21	Positive predictive value of a registerâ€based algorithm using the Danish National Registries to identify suicidal events. Pharmacoepidemiology and Drug Safety, 2018, 27, 1131-1138.	1.9	22
22	Polypharmacy and Potentially Inappropriate Medication in People with Dementia: A Nationwide Study. Journal of Alzheimer's Disease, 2018, 63, 383-394.	2.6	66
23	Glucocorticoids and the risk of schizophrenia spectrum disorder in childhood and adolescence – A Danish nationwide study. Schizophrenia Research, 2018, 199, 116-122.	2.0	10
24	Prescription drug use in pregnancy and variations according to prior psychiatric history. Pharmacoepidemiology and Drug Safety, 2018, 27, 105-113.	1.9	10
25	Association between global functioning at first schizophrenia diagnosis and treatment resistance. Microbial Biotechnology, 2018, 12, 1198-1202.	1.7	6
26	Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study. American Journal of Psychiatry, 2017, 174, 686-694.	7.2	103
27	Psychotropic Polypharmacy in Patients withÂDementia: Prevalence and Predictors. Journal of Alzheimer's Disease, 2017, 56, 707-716.	2.6	55
28	Predictors of Nonhospitalization and Functional Response in Clozapine Treatment. Journal of Clinical Psychopharmacology, 2017, 37, 148-154.	1.4	15
29	Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia. Schizophrenia Bulletin, 2017, 43, 1064-1069.	4.3	76
30	Psychopharmacological treatment of psychotic mania and psychotic bipolar depression compared to nonâ€psychotic mania and nonâ€psychotic bipolar depression. Bipolar Disorders, 2017, 19, 505-512.	1.9	14
31	Do Statins Have Antidepressant Effects?. CNS Drugs, 2017, 31, 335-343.	5.9	22
32	Câ€reactive protein levels and treatment resistance in schizophrenia—A Danish populationâ€based cohort study. Human Psychopharmacology, 2017, 32, e2632.	1.5	10
33	Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia. American Journal of Psychiatry, 2017, 174, 990-998.	7.2	106
34	Metabolic profile at first-time schizophrenia diagnosis: a population-based cross-sectional study. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 621-630.	2.2	13
35	Association between Global Assessment of Functioning scores and indicators of functioning, severity, and prognosis in first-time schizophrenia. Clinical Epidemiology, 2016, Volume 8, 323-332.	3.0	18
36	Geographical Variation in Antipsychotic Drug Use in Elderly Patients with Dementia: A Nationwide Study. Journal of Alzheimer's Disease, 2016, 54, 1183-1192.	2.6	10

CHRISTIANE GASSE

#	Article	IF	CITATIONS
37	Inequalities in Access to Treatment and Care for Patients with Dementia and Immigrant Background: A Danish Nationwide Study. Journal of Alzheimer's Disease, 2016, 54, 505-514.	2.6	40
38	Trends in the psychopharmacological treatment of bipolar disorder: a nationwide register-based study. Acta Neuropsychiatrica, 2016, 28, 75-84.	2.1	38
39	The Effect of Concomitant Treatment With SSRIs and Statins: A Population-Based Study. American Journal of Psychiatry, 2016, 173, 807-815.	7.2	63
40	Anti-inflammatory Agents for the Treatment of Depression in the Light of Comorbid Cardiovascular Disease. , 2016, , 445-465.		0
41	Impact of varying outcomes and definitions of suicidality on the associations of antiepileptic drugs and suicidality: comparisons from <scp>UK Clinical Practice Research Datalink (CPRD)</scp> and <scp>Danish</scp> national registries (DNR). Pharmacoepidemiology and Drug Safety, 2016, 25, 142-155.	1.9	12
42	Postoperative Treatment of Pain after Hip Fracture in Elderly Patients with Dementia. Dementia and Geriatric Cognitive Disorders, 2016, 41, 181-191.	1.5	38
43	Inverse association between urbanicity and treatment resistance in schizophrenia. Schizophrenia Research, 2016, 174, 150-155.	2.0	18
44	Concomitant NSAID use during antipsychotic treatment and risk of 2-year relapse – a population-based study of 16,253 incident patients with schizophrenia. Expert Opinion on Pharmacotherapy, 2016, 17, 1055-1062.	1.8	11
45	Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry,the, 2016, 3, 358-366.	7.4	105
46	Time Trends in Antipsychotic Drug Use in Patients with Dementia: A Nationwide Study. Journal of Alzheimer's Disease, 2015, 49, 211-220.	2.6	32
47	Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study. European Neuropsychopharmacology, 2015, 25, 857-863.	0.7	40
48	Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes. Brain and Behavior, 2015, 5, e00338.	2.2	55
49	Frequent use of opioids in patients with dementia and nursing home residents: A study of the entire elderly population of Denmark. Alzheimer's and Dementia, 2015, 11, 691-699.	0.8	82
50	Major depression and first-time hospitalization with ischemic heart disease, cardiac procedures and mortality in the general population: A retrospective Danish population-based cohort study. European Journal of Preventive Cardiology, 2014, 21, 532-540.	1.8	30
51	Pattern and predictors of sick leave among users of antidepressants: A Danish retrospective register-based cohort study. Journal of Affective Disorders, 2013, 151, 959-966.	4.1	11
52	Chronic Somatic Comorbidity and Excess Mortality Due to Natural Causes in Persons with Schizophrenia or Bipolar Affective Disorder. PLoS ONE, 2011, 6, e24597.	2.5	173
53	Antipsychotic Polypharmacy and Risk of Death From Natural Causes in Patients With Schizophrenia. Journal of Clinical Psychiatry, 2010, 71, 103-108.	2.2	114
54	Preadmission use of SSRIs alone or in combination with NSAIDs and 30-day mortality after peptic ulcer bleeding. Scandinavian Journal of Gastroenterology, 2009, 44, 1288-1295.	1.5	9

CHRISTIANE GASSE

#	Article	IF	CITATIONS
55	Use of Statins and Risk of Hospitalization With Dementia. Alzheimer Disease and Associated Disorders, 2009, 23, 18-22.	1.3	22
56	Somatic Hospital Contacts, Invasive Cardiac Procedures, and Mortality From Heart Disease in Patients With Severe Mental Disorder. Archives of General Psychiatry, 2009, 66, 713.	12.3	245
57	Risk of Hospitalization for Acute Pancreatitis Associated with Conventional and Atypical Antipsychotics: A Population-Based Case-Control Study. Pharmacotherapy, 2008, 28, 27-34.	2.6	14
58	Selective Serotonin Reuptake Inhibitors and Risk of Acute Pancreatitis. Journal of Clinical Psychopharmacology, 2007, 27, 259-262.	1.4	23
59	Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. European Journal of Clinical Pharmacology, 2005, 61, 327-335.	1.9	67
60	Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thrombosis and Haemostasis, 2005, 94, 537-543.	3.4	73
61	Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. European Journal of Clinical Pharmacology, 2004, 60, 595-602.	1.9	33
62	Drug interactions in primary care: Impact of a new algorithm on risk determination*1. Clinical Pharmacology and Therapeutics, 2004, 76, 85-96.	4.7	59
63	Lack of Evidence for Association of High Altitude Pulmonary Edema and Polymorphisms of the NO Pathway. High Altitude Medicine and Biology, 2003, 4, 355-366.	0.9	32
64	Quality markers of drug information on the internet: an evaluation of sites about St. John's Wort. American Journal of Medicine, 2002, 113, 740-745.	1.5	43
65	Factors associated with differences in antihypertensive drug treatment: Results from the MONICA Augsburg Population Surveys 1989/90 and 1994/95. International Journal of Public Health, 2002, 47, 128-139.	2.6	13
66	Population Trends in Antihypertensive Drug Use. Journal of Clinical Epidemiology, 1999, 52, 695-703.	5.0	29